Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have earned an average recommendation of “Buy” from the eight research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $6.40.

A number of analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 8th. HC Wainwright set a $9.00 target price on shares of Aptose Biosciences and gave the stock a “buy” rating in a research report on Thursday, December 13th. Roth Capital reissued a “buy” rating on shares of Aptose Biosciences in a research report on Wednesday, December 12th. B. Riley assumed coverage on shares of Aptose Biosciences in a research report on Friday, November 16th. They set a “buy” rating and a $5.00 target price for the company. Finally, Citigroup assumed coverage on shares of Aptose Biosciences in a research report on Friday, January 25th. They set an “outperform” rating and a $6.00 target price for the company.

In other Aptose Biosciences news, CFO Gregory K. Chow bought 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The stock was purchased at an average price of $1.75 per share, with a total value of $26,250.00. Following the transaction, the chief financial officer now owns 122,014 shares in the company, valued at $213,524.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Noven Financial Group Inc. acquired a new stake in Aptose Biosciences in the fourth quarter valued at approximately $27,000. Geode Capital Management LLC acquired a new stake in Aptose Biosciences in the fourth quarter valued at approximately $33,000. Citadel Advisors LLC acquired a new stake in Aptose Biosciences in the third quarter valued at approximately $125,000. Patriot Financial Group Insurance Agency LLC grew its position in Aptose Biosciences by 11.4% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 5,890 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Aptose Biosciences by 1,130.9% in the third quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock valued at $477,000 after acquiring an additional 168,501 shares in the last quarter. 8.19% of the stock is owned by hedge funds and other institutional investors.

Shares of APTO stock opened at $1.90 on Friday. The stock has a market cap of $70.99 million, a PE ratio of -2.21 and a beta of 1.59. Aptose Biosciences has a 1-year low of $1.57 and a 1-year high of $4.55.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). As a group, research analysts anticipate that Aptose Biosciences will post -0.68 earnings per share for the current year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Read More: Buy-Side Analysts

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.